如何在有疫苗可用的情况下，仍以合乎道德的方式测试严重急性呼吸综合征冠状病毒 2 型疫苗。
How to Test Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines Ethically Even After One Is Available.
机构信息
Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, New Jersey, USA.
Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, New Jersey, USA.
出版信息
Clin Infect Dis. 2021 Dec 16;73(12):2332-2334. doi: 10.1093/cid/ciab182.
Abstract
Although vaccines against severe acute respiratory syndrome coronavirus 2 have now been found safe and efficacious, there remains an urgent global health need to test both these vaccines and additional vaccines against the same virus. Under variable conditions, either standard or unusual designs would for both familiar and often-missed reasons make continued testing possible and ethical.
摘要
尽管针对严重急性呼吸综合征冠状病毒 2 的疫苗现在已被证明是安全有效的，但仍迫切需要在全球范围内测试这些疫苗和针对同一病毒的其他疫苗。在不同的条件下，出于常见和经常被忽视的原因，无论是标准设计还是非标准设计，都可以继续进行测试，这在伦理上也是可行的。
相似文献
1
How to Test Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines Ethically Even After One Is Available.如何在有疫苗可用的情况下，仍以合乎道德的方式测试严重急性呼吸综合征冠状病毒 2 型疫苗。
Clin Infect Dis. 2021 Dec 16;73(12):2332-2334. doi: 10.1093/cid/ciab182.
2
COVID-19: Coronavirus Vaccine Development Updates.COVID-19：冠状病毒疫苗研发进展。
Front Immunol. 2020 Dec 23;11:602256. doi: 10.3389/fimmu.2020.602256. eCollection 2020.
3
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.CEPI/BC 2020 年 3 月 12-13 日会议共识总结报告：评估 COVID-19 疫苗引起疾病增强的风险。
Vaccine. 2020 Jun 26;38(31):4783-4791. doi: 10.1016/j.vaccine.2020.05.064. Epub 2020 May 25.
4
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19（Sars-Cov-2）的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
5
Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).2019年冠状病毒病（COVID-19）当前疫苗研发策略综述
Toxicol Pathol. 2020 Oct;48(7):800-809. doi: 10.1177/0192623320959090. Epub 2020 Sep 14.
6
Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?针对冠状病毒感染的疫苗候选者。COVID-19 处于什么位置？
Viruses. 2020 Aug 7;12(8):861. doi: 10.3390/v12080861.
7
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.SARS-CoV-2 变体和 COVID-19 疫苗：当前的挑战与未来策略。
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
8
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
9
Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.绘制 SARS、MERS 和 SARS-CoV-2 疫苗的技术图谱。
Drug Dev Ind Pharm. 2021 Apr;47(4):673-684. doi: 10.1080/03639045.2021.1908343. Epub 2021 Apr 7.
10
Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.基于 SARS 和 MERS 疫苗研发进展的 COVID-19 疫苗研发的挑战与前景。
Transbound Emerg Dis. 2021 May;68(3):1111-1124. doi: 10.1111/tbed.13804. Epub 2020 Sep 23.
引用本文的文献
1
Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection.建立非人灵长类动物对疫苗的反应模型，以确定 SARS-CoV-2 保护的机制相关性。
Elife. 2022 Jul 8;11:e75427. doi: 10.7554/eLife.75427.
2
Pandemic vaccine testing: Combining conventional and challenge studies.大流行疫苗测试：常规研究与挑战研究相结合。
Pharmacoepidemiol Drug Saf. 2022 Jun;31(6):710-715. doi: 10.1002/pds.5429. Epub 2022 Mar 31.
3
Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.多臂临床试验中的适应性治疗分配和选择：贝叶斯视角。
BMC Med Res Methodol. 2022 Feb 20;22(1):50. doi: 10.1186/s12874-022-01526-8.
4
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact.接种疫苗人群中的 SARS-CoV-2 突破感染：测量、原因和影响。
Nat Rev Immunol. 2022 Jan;22(1):57-65. doi: 10.1038/s41577-021-00662-4. Epub 2021 Dec 7.
5
Do coronavirus vaccine challenge trials have a distinctive generalisability problem?新冠病毒疫苗挑战试验是否存在独特的可推广性问题？
J Med Ethics. 2022 Sep;48(9):586-589. doi: 10.1136/medethics-2020-107109. Epub 2021 Jun 7.
6
COVID vaccine efficacy against the B.1.351 ("South African") variant-The urgent need to lay the groundwork for possible future challenge studies.新冠疫苗对B.1.351（“南非”）变种的效力——为未来可能的挑战研究奠定基础的迫切需求
Hum Vaccin Immunother. 2022 Dec 31;18(1):1917240. doi: 10.1080/21645515.2021.1917240. Epub 2021 Apr 27.
本文引用的文献
1
Force of infection: a determinant of vaccine efficacy?感染力：疫苗效力的一个决定因素？
NPJ Vaccines. 2021 Apr 12;6(1):51. doi: 10.1038/s41541-021-00316-5.
2
Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.COVID-19 人体挑战研究的伦理可接受性的关键标准：世卫组织工作组的报告。
Vaccine. 2021 Jan 22;39(4):633-640. doi: 10.1016/j.vaccine.2020.10.075. Epub 2020 Oct 28.
3
The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials.2019冠状病毒病疫苗试验中持续使用安慰剂的伦理问题
JAMA. 2021 Jan 19;325(3):219-220. doi: 10.1001/jama.2020.25053.
4
COVID-19 vaccine trial ethics once we have efficacious vaccines.一旦我们有了有效的新冠疫苗，新冠疫苗试验伦理。
Science. 2020 Dec 11;370(6522):1277-1279. doi: 10.1126/science.abf5084. Epub 2020 Dec 3.
5
Placebo-Controlled Trials of Covid-19 Vaccines - Why We Still Need Them.新冠疫苗的安慰剂对照试验——我们为何仍需要它们。
N Engl J Med. 2021 Jan 14;384(2):e2. doi: 10.1056/NEJMp2033538. Epub 2020 Dec 2.
6
Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential.对新冠疫苗试验的新结果保密至关重要。
Lancet. 2020 Nov 21;396(10263):1611-1613. doi: 10.1016/S0140-6736(20)32259-5. Epub 2020 Oct 27.
7
Opinion: For now, it's unethical to use human challenge studies for SARS-CoV-2 vaccine development.观点：目前，将人体挑战试验用于新冠病毒疫苗研发是不道德的。
Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28538-28542. doi: 10.1073/pnas.2021189117. Epub 2020 Oct 29.
8
First vaccine may stymie hunt for better ones.首款疫苗可能会阻碍对更优疫苗的探索。
Science. 2020 Oct 23;370(6515):389-390. doi: 10.1126/science.370.6515.389.
9
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.用于评估 COVID-19 疫苗试验疗效的临床终点。
Ann Intern Med. 2021 Feb;174(2):221-228. doi: 10.7326/M20-6169. Epub 2020 Oct 22.
10
Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.为什么持续存在的不确定性不是推迟冠状病毒疫苗挑战试验的理由。
J Med Ethics. 2020 Dec;46(12):808-812. doi: 10.1136/medethics-2020-106501. Epub 2020 Jul 13.
Zotero 插件